Danuta M Skowronski1,2, Solmaz Setayeshgar1, Macy Zou3, Natalie Prystajecky4,5, John R Tyson4,5, Hind Sbihi2,3, Chris D Fjell4, Eleni Galanis1,2, Monika Naus1,2, David M Patrick1,2, Shiraz El Adam1, May A Ahmed1, Shinhye Kim1, Bonnie Henry2,6, Linda M N Hoang4,5, Manish Sadarangani7,8, Agatha N Jassem4,5, Mel Krajden4,5. 1. Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada. 2. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. 3. Data and Analytics Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada. 4. Public Health Laboratory, BC Centre for Disease Control, Vancouver, British Columbia, Canada. 5. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 6. Office of the Provincial Health Officer, Ministry of Health, Victoria, British Columbia, Canada. 7. Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada. 8. Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: In British Columbia, Canada, most adults 50-69 years old became eligible for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in April 2021, with chimpanzee adenoviral vectored vaccine (ChAdOx1) restricted to ≥55-year-olds and second doses deferred ≥6 weeks to optimize single-dose coverage. METHODS: Among adults 50-69 years old, single-dose messenger RNA (mRNA) and ChAdOx1 vaccine effectiveness (VE) against SARS-CoV-2 infection and hospitalization, including variant-specific, was assessed by test-negative design between 4 April and 2 October 2021. RESULTS: Single-dose VE included 11 861 cases and 99 544 controls. Median of postvaccination follow-up was 32 days (interquartile range, 15-52 days). Alpha, Gamma, and Delta variants comprised 23%, 18%, and 56%, respectively, of genetically characterized viruses. At 21-55 days postvaccination, single-dose mRNA and ChAdOx1 VE (95% confidence interval [CI]) was 74% (71%-76%) and 59% (53%-65%) against any infection and 86% (80%-90%) and 94% (85%-97%) against hospitalization, respectively. VE (95% CI) was similar against Alpha and Gamma infections for mRNA (80% [76%-84%] and 80% [75%-84%], respectively) and ChAdOx1 (69% [60%-76%] and 66% [56%-73%], respectively). mRNA VE was lower at 63% (95% CI, 56%-69%) against Delta but 85% (95% CI, 71%-92%) against Delta-associated hospitalization (nonestimable for ChAdOx1). CONCLUSIONS: A single mRNA or ChAdOx1 vaccine dose gave important protection against SARS-CoV-2, including early variants of concern. ChAdOx1 VE was lower against infection, but 1 dose of either vaccine reduced the hospitalization risk by >85% to at least 8 weeks postvaccination. Findings inform program options, including longer dosing intervals.
BACKGROUND: In British Columbia, Canada, most adults 50-69 years old became eligible for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in April 2021, with chimpanzee adenoviral vectored vaccine (ChAdOx1) restricted to ≥55-year-olds and second doses deferred ≥6 weeks to optimize single-dose coverage. METHODS: Among adults 50-69 years old, single-dose messenger RNA (mRNA) and ChAdOx1 vaccine effectiveness (VE) against SARS-CoV-2 infection and hospitalization, including variant-specific, was assessed by test-negative design between 4 April and 2 October 2021. RESULTS: Single-dose VE included 11 861 cases and 99 544 controls. Median of postvaccination follow-up was 32 days (interquartile range, 15-52 days). Alpha, Gamma, and Delta variants comprised 23%, 18%, and 56%, respectively, of genetically characterized viruses. At 21-55 days postvaccination, single-dose mRNA and ChAdOx1 VE (95% confidence interval [CI]) was 74% (71%-76%) and 59% (53%-65%) against any infection and 86% (80%-90%) and 94% (85%-97%) against hospitalization, respectively. VE (95% CI) was similar against Alpha and Gamma infections for mRNA (80% [76%-84%] and 80% [75%-84%], respectively) and ChAdOx1 (69% [60%-76%] and 66% [56%-73%], respectively). mRNA VE was lower at 63% (95% CI, 56%-69%) against Delta but 85% (95% CI, 71%-92%) against Delta-associated hospitalization (nonestimable for ChAdOx1). CONCLUSIONS: A single mRNA or ChAdOx1 vaccine dose gave important protection against SARS-CoV-2, including early variants of concern. ChAdOx1 VE was lower against infection, but 1 dose of either vaccine reduced the hospitalization risk by >85% to at least 8 weeks postvaccination. Findings inform program options, including longer dosing intervals.
Authors: Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Chris Robertson; Julia Stowe; Elise Tessier; Ruth Simmons; Simon Cottrell; Richard Roberts; Mark O'Doherty; Kevin Brown; Claire Cameron; Diane Stockton; Jim McMenamin; Mary Ramsay Journal: BMJ Date: 2021-05-13
Authors: Samuel J Vidal; Ai-Ris Y Collier; Jingyou Yu; Katherine McMahan; Lisa H Tostanoski; John D Ventura; Malika Aid; Lauren Peter; Catherine Jacob-Dolan; Tochi Anioke; Aiquan Chang; Huahua Wan; Ricardo Aguayo; Debby Ngo; Robert E Gerszten; Michael S Seaman; Dan H Barouch Journal: J Virol Date: 2021-06-24 Impact factor: 5.103
Authors: Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks Journal: N Engl J Med Date: 2020-12-30 Impact factor: 91.245
Authors: Catherine A Hogan; Agatha N Jassem; Hind Sbihi; Yayuk Joffres; John R Tyson; Kyle Noftall; Marsha Taylor; Tracy Lee; Chris Fjell; Amanda Wilmer; John Galbraith; Marc G Romney; Bonnie Henry; Mel Krajden; Eleni Galanis; Natalie Prystajecky; Linda M N Hoang Journal: Emerg Infect Dis Date: 2021-08-13 Impact factor: 6.883
Authors: Tina Schmidt; Verena Klemis; David Schub; Sophie Schneitler; Matthias C Reichert; Heinrike Wilkens; Urban Sester; Martina Sester; Janine Mihm Journal: Am J Transplant Date: 2021-09-06 Impact factor: 8.086
Authors: Merryn Voysey; Sue Ann Costa Clemens; Shabir A Madhi; Lily Y Weckx; Pedro M Folegatti; Parvinder K Aley; Brian Angus; Vicky L Baillie; Shaun L Barnabas; Qasim E Bhorat; Sagida Bibi; Carmen Briner; Paola Cicconi; Elizabeth A Clutterbuck; Andrea M Collins; Clare L Cutland; Thomas C Darton; Keertan Dheda; Christina Dold; Christopher J A Duncan; Katherine R W Emary; Katie J Ewer; Amy Flaxman; Lee Fairlie; Saul N Faust; Shuo Feng; Daniela M Ferreira; Adam Finn; Eva Galiza; Anna L Goodman; Catherine M Green; Christopher A Green; Melanie Greenland; Catherine Hill; Helen C Hill; Ian Hirsch; Alane Izu; Daniel Jenkin; Carina C D Joe; Simon Kerridge; Anthonet Koen; Gaurav Kwatra; Rajeka Lazarus; Vincenzo Libri; Patrick J Lillie; Natalie G Marchevsky; Richard P Marshall; Ana V A Mendes; Eveline P Milan; Angela M Minassian; Alastair McGregor; Yama F Mujadidi; Anusha Nana; Sherman D Padayachee; Daniel J Phillips; Ana Pittella; Emma Plested; Katrina M Pollock; Maheshi N Ramasamy; Adam J Ritchie; Hannah Robinson; Alexandre V Schwarzbold; Andrew Smith; Rinn Song; Matthew D Snape; Eduardo Sprinz; Rebecca K Sutherland; Emma C Thomson; M Estée Török; Mark Toshner; David P J Turner; Johan Vekemans; Tonya L Villafana; Thomas White; Christopher J Williams; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Andrew J Pollard Journal: Lancet Date: 2021-02-19 Impact factor: 79.321
Authors: Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Eileen Gallagher; Ruth Simmons; Simon Thelwall; Julia Stowe; Elise Tessier; Natalie Groves; Gavin Dabrera; Richard Myers; Colin N J Campbell; Gayatri Amirthalingam; Matt Edmunds; Maria Zambon; Kevin E Brown; Susan Hopkins; Meera Chand; Mary Ramsay Journal: N Engl J Med Date: 2021-07-21 Impact factor: 91.245
Authors: Danuta M Skowronski; Solmaz Setayeshgar; Macy Zou; Natalie Prystajecky; John R Tyson; Eleni Galanis; Monika Naus; David M Patrick; Hind Sbihi; Shiraz El Adam; Bonnie Henry; Linda M N Hoang; Manish Sadarangani; Agatha N Jassem; Mel Krajden Journal: Clin Infect Dis Date: 2022-04-09 Impact factor: 9.079
Authors: Melissa M Higdon; Brian Wahl; Carli B Jones; Joseph G Rosen; Shaun A Truelove; Anurima Baidya; Anjalika A Nande; Parisa A ShamaeiZadeh; Karoline K Walter; Daniel R Feikin; Minal K Patel; Maria Deloria Knoll; Alison L Hill Journal: Open Forum Infect Dis Date: 2022-04-18 Impact factor: 4.423
Authors: Diego Fernández-Lázaro; Manuel Garrosa; Nerea Sánchez-Serrano; Evelina Garrosa; Elena Jiménez-Callejo; María Dolores Pardo Yanguas; Juan Mielgo-Ayuso; Jesús Seco-Calvo Journal: Vaccines (Basel) Date: 2022-07-22